IPOs/Nasdaq Global Select Market/2026/Bambusa Therapeutics, Inc.

Bambusa Therapeutics, Inc. BBTX

Bambusa Therapeutics, Inc. (BBTX) priced its IPO on Nasdaq Global Select Market on October 30, 2026 at $16.00 a share. Develops next-generation, long-acting precision bispecific antibodies for immunology and inflammation diseases. Based in Boston, Massachusetts.

Registered
Priced
TradingNot yet
Offer price
$16.00
Raised
Not given
Shares offered
10,555,555 shares
Lock-up
180 days
See the prospectus →

The company

Bambusa Therapeutics, Inc. is based in Boston, Massachusetts and develops next-generation, long-acting precision bispecific antibodies for immunology and inflammation diseases. It sold 10,555,555 shares at $16.00 per share.

The company will use the $152.4 million in net proceeds to fund continued development of BBT001, BBT002, and additional R&D of BBT003 and BBT004, plus capital expenditures, working capital, and general corporate purposes. After the offering, Salvia Investment holds 17.4%, Shanshan Xu, M.D., Ph.D., M.B.A. holds 16.9%, and Entities Affiliated with RA Capital hold 8.8%.

Where the money goes

approximately $90.0 million to fund continued development of BBT001
approximately $40.0 million to fund continued development of BBT002
fund additional R&D of BBT003 and BBT004
capital expenditures, working capital, and general corporate purposes

Revenue and results

Net result, Six Months Ended June 30, 2026$22,360 loss
Net result, Six Months Ended June 30, 2025$14,747 loss
Net result, Year Ended December 31, 2025$41,087 loss
Net result, Period from March 14, 2024 (Inception) to December 31, 2024$13,741 loss

The risks it lists first

Limited operating history makes evaluation difficult
Significant losses and negative cash flows expected to continue
Substantial competition from other biotechnology companies